 ATLANTA--BUSINESS WIRE--Virios Therapeutics, Inc. Nasdaq: VIRI, a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, announced today that it is entering a collaboration with Dr. Michael Camilleri of the Mayo Clinic to explore the role of antiviral therapy in managing Irritable Bowel Syndrome IBS. The first step in the collaboration is focused on designing a phase 2 proof of concept study to tre 